Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1753 - Ex vivo cytotoxicity and in vivo antitumor activity of a novel highly selective STAT3 inhibitor YHO-1701 for ovarian and endometrial cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Ovarian Cancer


Kosei Hasegawa


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


K. Hasegawa1, K. Taniguchi2, S. Sato1, A. Yoshinaga2, M. Tsugane2, M. Nishiyama3, K. Fujiwara1

Author affiliations

  • 1 Gynecologic Oncology, Saitama Medical University International Medical Center, 350-1298 - Hidaka, Saitama/JP
  • 2 Yakult Central Institute, Yakult Honsha Co., Ltd., 1868650 - Kunitachi, Tokyo/JP
  • 3 Molecular And Cellular Pharmacology And Oncology, Gunma University, 371-8511 - Maebashi/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1753


The signal transducer and activator of transcription (STAT) 3 plays a critical role in the regulation of cell growth, metastasis, and survival. STAT3 signaling is constitutively activated in various cancers including gynecological cancers. We evaluated the efficacy of a novel selective STAT3 inhibitor, YHO-1701, ex vivo and in vivo for ovarian and endometrial cancer.


An expression profile of YHO-1701 treated cells was compared with that of other STAT3 inhibitors or its upstream Janus kinase inhibitor by RNA sequencing. The downstream signaling of YHO-1701 was investigated by western blot. Patients derived primary cancer cells (PDCs) were isolated from surgical specimens or ascites cells from ovarian or endometrial cancer patients, and the growth inhibitory effect of YHO-1701 on PDCs was evaluated by standard colorimetric assays. Antitumor activity of YHO-1701 was assessed using an SKOV3 abdominal dissemination xenograft model.


We investigated the specificity of YHO-1701 by pathway analysis using RNA sequencing results of the cells treated with or without each inhibitor and found YHO-1701 regulated STAT3 signaling more tightly than others did. We confirmed decreased levels of pSTAT3 S727, Survivin, and c-Myc in the cells treated with YHO-1701. A total of 41 PDCs were treated with YHO-1701 and showed a remarkable growth inhibition compared with the control group (P < 0.0007 and P < 0.0001 for ovarian and endometrial cancer cells, respectively). We tested the potential antitumor activity of orally administrated YHO-1701 in a mouse intraperitoneal dissemination model of ovarian cancer using SKOV3. We observed decreased numbers of peritoneal metastasis in mice treated with YHO-1701 compared with those treated with vehicle control (P < 0.05).


Our results demonstrated the efficacy of YHO-1701 for ovarian and endometrial cancer both ex vivo and in vivo through STAT3 signaling.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Yakult Honsha.


K. Hasegawa: Research grant / Funding (self): Yakult. K. Taniguchi: Full / Part-time employment: Yakult. A. Yoshinaga: Full / Part-time employment: Yakult. M. Tsugane: Full / Part-time employment: Yakut. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.